Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

South Korea's Samsung Biologics signs $231 million supply deal with GSK

Published 22/05/2020, 03:04
Updated 22/05/2020, 03:05
© Reuters.

© Reuters.

SEOUL (Reuters) - South Korean contract drugs manufacturer Samsung (LON:0593xq) Biologics Co Ltd (KS:207940) said on Friday it had signed a deal worth more than $231 million(188.91 million pounds) with GlaxoSmithKline PLC (GSK) (L:GSK) to supply biopharmaceutical products over the next eight years.

The biotech arm of Samsung Group will start with manufacturing drugs for autoimmune disease lupus for GSK with the aim to expand to making other drugs for the British drugmaker, an official at Samsung Biologics told Reuters.

"Samsung Biologics entered the biopharma industry with the goal to help our clients bring valuable biological medicines to patients faster," CEO Kim Tae-han said in a statement.

The deal will initially cover commercial production of lupus drug Benlysta and first supply is expected in 2022.

In April, Samsung Biologics won a 442 billion won ($358 million) order from U.S. firm Vir Biotechnology Inc (O:VIR) to manufacture antibodies to potentially treat COVID-19, the respiratory disease caused by the novel coronavirus.

Samsung Biologics shares were up nearly 2%, while the broader KOSPI (KS11) was down 0.8% as of 0150 GMT.

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.